Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 263

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1B
Chunk 263
---
    )

    Net cash used in investing activities

    (574,817
    )

    (200,413
    )

    (173,980
    )

    Financing activities:

    Proceeds from issuance of common stock, net of $49,442 (2024), $22,735 (2023) and $7,758 (2022) transaction costs

    970,048

    369,019

    117,242

    Proceeds from exercise of stock options

    40,387

    19,925

    4,721

    Net cash provided by financing activities

    1,010,435

    388,944

    121,963

    Net change in cash, cash equivalents and restricted cash

    209,648

    22,224

    (167,222
    )

    Cash, cash equivalents and restricted cash - beginning of period

    56,197

    33,973

    201,195

    Cash, cash equivalents and restricted cash - end of period
     
    $
    265,845

    $
    56,197

    $
    33,973

    Components of cash, cash equivalents and restricted cash:

    Cash and cash equivalents
     
    $
    264,545

    $
    54,897

    $
    32,672

    Restricted cash
     
    $
    500

    —

    —

    Restricted cash, net of current portion

    800

    1,300

    1,301

    Cash, cash equivalents and restricted cash at end of period
     
    $
    265,845

    $
    56,197

    $
    33,973

    Non-cash investing and financing activities:

    Private company shares received under licensing arrangements
     
    $
    —

    $
    2,000

    $
    —

    Exercise of Radionetics Warrant
     
    $
    —

    $
    668

    $
    —

    Stock issued under Employee Stock Purchase Plan
     
    $
    4,224

    $
    2,291

    $
    1,618

    Stock options exercised receivable
     
    $
    76

    $
    166

    $
    —

    Receivable for common stock issuances
     
    $